These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25015735)

  • 1. Postprandial glucose-lowering effects of fermented red ginseng in subjects with impaired fasting glucose or type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
    Oh MR; Park SH; Kim SY; Back HI; Kim MG; Jeon JY; Ha KC; Na WT; Cha YS; Park BH; Park TS; Chae SW
    BMC Complement Altern Med; 2014 Jul; 14():237. PubMed ID: 25015735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Vuksan V; Sung MK; Sievenpiper JL; Stavro PM; Jenkins AL; Di Buono M; Lee KS; Leiter LA; Nam KY; Arnason JT; Choi M; Naeem A
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):46-56. PubMed ID: 16860976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.
    Vuksan V; Sievenpiper JL; Koo VY; Francis T; Beljan-Zdravkovic U; Xu Z; Vidgen E
    Arch Intern Med; 2000 Apr; 160(7):1009-13. PubMed ID: 10761967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ginseng berry saponins from panax ginseng on glucose metabolism of patients with prediabetes: A randomized, double-blinded, placebo-controlled, crossover trial.
    Gao J; Shi J; Ma X; Lu F; Fu C; Chen Z; Miao L; Qu H; Zhao Y; Zhang Y; Yang Z; Pan D; Zhu C; Li Q; Shi D
    Phytomedicine; 2024 Sep; 132():155842. PubMed ID: 39004031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of American ginseng (Panax quinquefolius L.) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial.
    Vuksan V; Xu ZZ; Jovanovski E; Jenkins AL; Beljan-Zdravkovic U; Sievenpiper JL; Mark Stavro P; Zurbau A; Duvnjak L; Li MZC
    Eur J Nutr; 2019 Apr; 58(3):1237-1245. PubMed ID: 29478187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
    Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitosan oligosaccharide (GO2KA1) improves postprandial glycemic response in subjects with impaired glucose tolerance and impaired fasting glucose and in healthy subjects: a crossover, randomized controlled trial.
    Jeong S; Min Cho J; Kwon YI; Kim SC; Yeob Shin D; Ho Lee J
    Nutr Diabetes; 2019 Nov; 9(1):31. PubMed ID: 31685797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proof-of-concept study to evaluate the efficacy and safety of BTI320 on post-prandial hyperglycaemia in Chinese subjects with pre-diabetes.
    Luk AOY; Zee BCY; Chong M; Ozaki R; Rausch CW; Chan MHM; Ma RCW; Kong APS; Chow FCC; Chan JCN
    BMC Endocr Disord; 2018 Aug; 18(1):59. PubMed ID: 30170579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.
    Samukawa Y; Omiya H; Watase H; Nozaki K; Sakai S; Nishimura R
    Adv Ther; 2016 Jul; 33(7):1215-30. PubMed ID: 27255763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Red ginseng powder fermented with probiotics exerts antidiabetic effects in the streptozotocin-induced mouse diabetes model.
    Jang SH; Park J; Kim SH; Choi KM; Ko ES; Cha JD; Lee YR; Jang H; Jang YS
    Pharm Biol; 2017 Dec; 55(1):317-323. PubMed ID: 27927080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis.
    Gui QF; Xu ZR; Xu KY; Yang YM
    Medicine (Baltimore); 2016 Feb; 95(6):e2584. PubMed ID: 26871778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
    Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
    Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Korean red ginseng improves glucose control in subjects with impaired fasting glucose, impaired glucose tolerance, or newly diagnosed type 2 diabetes mellitus.
    Bang H; Kwak JH; Ahn HY; Shin DY; Lee JH
    J Med Food; 2014 Jan; 17(1):128-34. PubMed ID: 24456363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fermented Red Ginseng Potentiates Improvement of Metabolic Dysfunction in Metabolic Syndrome Rat Models.
    Kho MC; Lee YJ; Park JH; Kim HY; Yoon JJ; Ahn YM; Tan R; Park MC; Cha JD; Choi KM; Kang DG; Lee HS
    Nutrients; 2016 Jun; 8(6):. PubMed ID: 27322312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effect of xylose consumption on postprandial hyperglycemia in Korean: a randomized double-blind, crossover design.
    Jun YJ; Lee J; Hwang S; Kwak JH; Ahn HY; Bak YK; Koh J; Lee JH
    Trials; 2016 Mar; 17(1):139. PubMed ID: 26979433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
    Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
    Baekdal M; Nielsen SW; Hansen CP; Storkholm JH; van Hall G; Hartmann B; Holst JJ; Vilsbøll T; Lund A; Knop FK
    Diabetes Care; 2024 Jan; 47(1):71-80. PubMed ID: 37703527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
    Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
    Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
    Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
    Diabetes Obes Metab; 2017 Oct; 19(10):1397-1407. PubMed ID: 28371205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.